Healx is a UK-based biotechnology company founded in 2014 that focuses on accelerating drug discovery and development for rare diseases using artificial intelligence (AI). The company has developed a next-generation AI platform that analyzes extensive drug and disease data to uncover new treatment opportunities. By combining AI-driven insights with scientific expertise, Healx advances promising drug candidates through preclinical development and clinical trials.

The company has launched 17 drug development programs targeting various rare diseases, including neurodegenerative, respiratory, kidney, oncology, and neuromuscular conditions. Its most advanced program is a combination therapy for fragile X syndrome, currently in a phase 2A clinical trial. Healx primarily works with repurposed drugs, leveraging existing compounds to explore new therapeutic uses, which helps reduce risk and development time.

Healx emphasizes patient-centric drug development, engaging with patient communities to inform research priorities and clinical trial designs. Its AI-driven platform and drug discovery services support pharmaceutical companies looking to enhance their rare disease portfolios and expedite drug development.